This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Articles

Treatment of Bulimia Nervosa With Topiramate in a Randomized, Double-Blind, Placebo-Controlled Trial, Part 1: Improvement in Binge and Purge Measures

Scott P. Hoopes, MD; Frederick W. Reimherr, MD; Dawson W. Hedges, MD; Norman R. Rosenthal, MD; Marc Kamin, MD; Rezaul Karim, PhD; Julie A. Capece, BA; and Debra Karvois, MS

Published: November 15, 2003

Article Abstract

Background: This randomized, double-blind, placebo-controlled trial was designed to assess the efficacy and safety of topiramate in bulimia nervosa.

Method: Patients with DSM-IV bulimia nervosa were randomly assigned in equal proportions to receive topiramate (N = 35) or placebo (N = 34) for 10 weeks (between April 1999 and Dec. 2000). Topiramate treatment was started at 25 mg/day and titrated by 25 to 50 mg/week to a maximum of 400 mg/day. The primary efficacy measure was mean weekly number of binge and/or purge days. Related outcome measures included mean weekly number of binge days and binge frequency, as well as mean weekly number of purge days and purge frequency.

Results: Sixty-four outpatients (33 placebo, 31 topiramate) were included in the intent-to-treat analysis. The median topiramate dose was 100 mg/day (range, 25-400 mg/day). Mean ± SD baseline number of weekly binge and/or purge days was 5.0 ± 1.6 for topiramate patients and 5.1 ± 1.5 for placebo patients. The primary efficacy measure, mean weekly number of binge and/or purge days, decreased 44.8% from baseline with topiramate versus 10.7% with placebo (p = .004). The mean weekly number of binge days decreased 48.2% with topiramate versus 17.7% with placebo (p = .015), and mean binge frequency decreased 49.2% with topiramate versus 28.0% with placebo (p = .071). The mean weekly number of purge days decreased 43.4% with topiramate versus 16.6% with placebo (p = .016), and mean purge frequency decreased 49.8% with topiramate versus 21.6% with placebo (p = .016). Three patients (2 placebo, 1 topiramate) discontinued from the trial due to adverse events.

Conclusion: Topiramate was associated with significant improvements in both binge and purge symptoms in this study population and represents a potential treatment for bulimia nervosa.

Volume: 64

Quick Links: Eating Disorders

Continue Reading…

Subscribe to read the entire article

$40.00

Buy this Article as a PDF

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Original Research

Young-Adult Social Outcomes of Attention-Deficit/Hyperactivity Disorder

ADHD that persisted into young-adulthood was associated with poorer outcomes in terms of education, employment, and emotional...

Read More...